Adipotide Research Guide: FTPP Vascular-Targeted Adipose Peptide
Adipotide is a chimeric peptidomimetic engineered to selectively induce apoptosis in the vasculature supporting white adipose tissue.
What is Adipotide?
Adipotide (FTPP) is a chimeric proapoptotic peptidomimetic developed in the Kolonin/Arap/Pasqualini vascular-targeting program at MD Anderson. It represents a fundamentally different approach to adipose research than hormone-based incretin work.
Mechanism of action
The homing domain CKGGRAKDC binds prohibitin — a mitochondrial and cell-surface protein selectively displayed on the vascular endothelium of white adipose tissue. The fused D(KLAKLAK)₂ pro-apoptotic domain internalizes and disrupts mitochondrial membranes, killing the endothelial cell and pruning adipose vasculature.
Adipocytes deprived of vascular support undergo apoptosis and reabsorption, driving reductions in fat mass in preclinical rodent and non-human primate research.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is Adipotide?
Adipotide (FTPP — Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic consisting of a homing sequence (CKGGRAKDC) that binds prohibitin on adipose vasculature, fused to a pro-apoptotic sequence (D(KLAKLAK)₂) that disrupts mitochondrial membranes.
Mechanism?
The homing peptide binds prohibitin selectively expressed on the endothelium of white-adipose-tissue capillaries. The proapoptotic domain then internalizes and lyses mitochondrial membranes of the endothelial cell, pruning adipose vasculature and driving adipocyte loss.
Published data?
Preclinical work in obese non-human primates (Kolonin lab, MD Anderson) reported substantial weight loss without CNS or GI toxicity typical of hormone-based approaches.